M&A Deal Summary |
|
|---|---|
| Date | 2021-10-01 |
| Target | QInstruments |
| Sector | Medical Products |
| Buyer(s) | BICO |
| Deal Type | Add-on Acquisition |
| Deal Value | 61M EUR |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2016 |
| Sector | Life Science |
| Employees | 695 |
| Revenue | 1.9B SEK (2024) |
BICO is a bio convergence company that combines different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology. With a focus on the application areas of bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO was founded in 2016 and is based in Gothenburg, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| Country: Germany M&A | 1 of 1 |
| Year: 2021 M&A | 3 of 3 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-09-15 |
Hurel
North Brunswick Township, New Jersey, United States Hurel uses cell biology and microfluidics in a “chip” to help drug companies predict pre-clinically the drug candidates with the best chances of winning FDA approval. Hurel was founded in 2005 and is based in North Brunswick Township, New jersey. |
Buy | - |
